
Dato-DXd Plus Durvalumab ± Carboplatin Delivers Antitumor Activity in Advanced NSCLC
Frontline treatment with datopotamab deruxtecan-dlnk (Dato-DXd; Datroway) plus durvalumab (Imfinzi) with (cohort 4) or without (cohort 2) carboplatin elicited responses in patients with advanced or metastatic non–small cell lung cancer (NSCLC) regardless …